P. falciparum infected RBCs Inhibitors

The phrase "P. falciparum infected RBCs" refers to red blood cells (RBCs) that have been invaded by Plasmodium falciparum, the most pathogenic of the malaria-causing parasites. P. falciparum is responsible for the most severe form of malaria in humans.Once a human is bitten by an infected Anopheles mosquito, P. falciparum sporozoites enter the bloodstream and travel to the liver. There, they invade liver cells, multiply, and differentiate into merozoites. These merozoites then re-enter the bloodstream and begin the erythrocytic cycle by invading RBCs.

Inside RBCs, P. falciparum undergoes a complex life cycle. The merozoites transform into ring-stage trophozoites, which metabolize hemoglobin and grow into schizonts. The schizonts contain multiple merozoites, which, upon RBC rupture, are released to infect new erythrocytes. This cycle of invasion, growth, and rupture causes malaria, including fever, anemia, and, in severe cases, cerebral malaria.P. falciparum modifies the infected RBCs in several ways. It exports proteins to the RBC's surface, leading to the formation of knob-like structures. One such protein, PfEMP1, causes the infected RBCs to adhere to the endothelial lining of blood vessels, blocking the infected cells from being cleared in the spleen and leading to microvascular obstruction and tissue hypoxia.The adherence of infected RBCs to each other and to vascular walls, a process known as cytoadherence or sequestration, contributes to the pathogenesis of severe malaria. It can lead to complications such as placental malaria in pregnant women and cerebral malaria, which is associated with high mortality.